Experienced in Chronic T-Cell Leukemia (CTCL)

Dr. Henry K. Holland

Hematology | Oncology
Blood And Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
Accepting New Patients
Experienced in Chronic T-Cell Leukemia (CTCL)
Blood And Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Henry Holland is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Holland is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Childhood Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Holland is currently accepting new patients.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Specialist in GA
Hospital Affiliations
Northside Hospital Forsyth
Northside Hospital Cherokee
Northside Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

BLOOD AND MARROW TRANSPLANT GROUP OF GEORGIA
5670 Peachtree Dunwoody Rd Ne, Suite 1000, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Rituximab, Ibrutinib
Study Phase: Phase 2
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Fludarabine, Melphalan, Pembrolizumab
Study Phase: Phase 2
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Enrollment Status: Terminated
Publish Date: November 14, 2022
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: September 02, 2021
Intervention Type: Drug
Study Drug: MLN9708
Study Phase: Phase 2
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
Enrollment Status: Completed
Publish Date: April 17, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

44 Total Publications

A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.
Journal: Blood advances
Published: April 15, 2025
Similar Doctors
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Kevin H. Peacock
Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Kevin H. Peacock
Oncology

Suburban Hematology Oncology Associates

631 Professional Drive, Suite 450, 
Snellville, GA 
 (19.5 miles away)
770-963-8030
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Peacock is an Oncologist in Snellville, Georgia. Dr. Peacock is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Paget Disease of the Breast, and Breast Cancer. Dr. Peacock is currently accepting new patients.

Petros G. Nikolinakos
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Petros G. Nikolinakos
Oncology | Hematology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Petros G. Nikolinakos
Oncology | Hematology

University Cancer And Blood Center

3320 Old Jefferson Road, Building 700, 
Athens, GA 
 (53.9 miles away)
706-353-2990
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Petros Nikolinakos is a Hematologist and an Oncologist in Athens, Georgia. Dr. Nikolinakos is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Lung Cancer, Breast Cancer, Neuroendocrine Tumor, and Colorectal Cancer. Dr. Nikolinakos is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Vishal Ranpura
Hematology | Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Vishal Ranpura
Hematology | Oncology

Suburban Hematology Oncology Associates

631 Professional Drive, Suite 450, 
Snellville, GA 
 (19.5 miles away)
770-963-8030
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vishal Ranpura is a Hematologist and an Oncologist in Snellville, Georgia. Dr. Ranpura is rated as an Advanced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Febrile Neutropenia, Thrombocytopenia, Anemia, Agranulocytosis, and Orchiectomy. Dr. Ranpura is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holland's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile